Correction of hyperlipidemia: statin treatment at post-marketing the COMPLIANCE studó
Keywords:
atorvastatin, generic, statin, post-marketing researchAbstract
Currently, statins are the only lipid-lowering drugs, the use of which is accompanied by a significant improvement in the prognosis in cardiovascular diseases. The use of generic statins, given their lower cost, makes treatment more accessible to the population and is directly related to its effectiveness. To confirm the clinical equivalence of the generic drug to the original drug, additional post-marketing clinical trials are carried out. As an example, this article considers a study to assess the hypolipidemic efficacy, tolerability and safety of the generic atorvastatin Tulip (Open Multicenter observational study of the efficacy and safety of Tulip®, a generic atorvastatin, in patients with dyslipidemia - COMPLIANCE).